Answers are grounded in this paper and cite their sources.
Axillary-node–negative breast cancer develops in approximately 70,000 women in the United States each year. Local surgery, radiotherapy, or both lead to long-term survival in the great majority (approximately 70 percent) of such women. Most do not have distant micrometastases and therefore do not require systemic therapy. The four articles on systemic adjuvant therapy in this issue of the Journal 1 2 3 4 are important first steps in the long journey toward the goal of eliminating micrometastases and curing the disease in the women whose cancer will recur. How should these results affect current treatment for node-negative breast cancer in the general population?The . . .
No takes yet. Share an insight, caveat, or question.
William McGuire (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: